scholarly journals Chronic Fatigue Syndrome

2021 ◽  
Vol 18 ◽  
pp. 17-23
Author(s):  
B. Sue Graves ◽  
Sigourney Kame

Chronic fatigue syndrome is an enduring disease, characterized by a level of persistent fatigue for 6 months or a longer time period. At this time, the etiology is unknown. The other symptoms individuals effected by chronic fatigue syndrome, may experience are sore throat, headaches, impaired cognition, depression, sleep disturbances, and many others. While the diagnosis of chronic fatigue syndrome can be challenging, the Center for Disease Control (CDC) has a set of guidelines to help characterize the presence of this condition in patients. Chronic fatigue syndrome has far-reaching consequences impacting an individual’s physical and mental wellbeing. The best approach in helping these individuals to still engage in physical activity is through gentle, lowlevel exercise program with the use of patient feedback to individualize the treatment as well as providing guidance and support through support groups and therapy as prescribed by a medical professional.

2021 ◽  
Vol 8 ◽  
pp. 204993612110093
Author(s):  
Sonia Poenaru ◽  
Sara J. Abdallah ◽  
Vicente Corrales-Medina ◽  
Juthaporn Cowan

Coronavirus disease 2019 (COVID-19) is a viral infection which can cause a variety of respiratory, gastrointestinal, and vascular symptoms. The acute illness phase generally lasts no more than 2–3 weeks. However, there is increasing evidence that a proportion of COVID-19 patients experience a prolonged convalescence and continue to have symptoms lasting several months after the initial infection. A variety of chronic symptoms have been reported including fatigue, dyspnea, myalgia, exercise intolerance, sleep disturbances, difficulty concentrating, anxiety, fever, headache, malaise, and vertigo. These symptoms are similar to those seen in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), a chronic multi-system illness characterized by profound fatigue, sleep disturbances, neurocognitive changes, orthostatic intolerance, and post-exertional malaise. ME/CFS symptoms are exacerbated by exercise or stress and occur in the absence of any significant clinical or laboratory findings. The pathology of ME/CFS is not known: it is thought to be multifactorial, resulting from the dysregulation of multiple systems in response to a particular trigger. Although not exclusively considered a post-infectious entity, ME/CFS has been associated with several infectious agents including Epstein–Barr Virus, Q fever, influenza, and other coronaviruses. There are important similarities between post-acute COVID-19 symptoms and ME/CFS. However, there is currently insufficient evidence to establish COVID-19 as an infectious trigger for ME/CFS. Further research is required to determine the natural history of this condition, as well as to define risk factors, prevalence, and possible interventional strategies.


2017 ◽  
Vol 22 (4) ◽  
pp. 1011-1016 ◽  
Author(s):  
Fatemeh Mahjoub ◽  
Roshanak Salari ◽  
Mohammad Reza Noras ◽  
Mahdi Yousefi

Fibromyalgia and chronic fatigue syndrome are disorders that often occur simultaneously and are characterized by widespread pain and persistent fatigue. The patients are associated with disability and impairment social and physical functions. There are many remedies in traditional Persian medicine suggested for management of the disease complaints. The aim of this study was to investigate the clinical presentations and pathophysiology of disorders with the basic and principal textbook of traditional Persian medicine written by Avicenna ( Canon of Medicine). According to Persian medicine, the term E’aya can be matched by mentioned disorders. Avicenna believed that strenuous activities play an important role in the beginning of some types of fatigue. He classified fatigue into 4 groups, and in each type the clinical symptoms varied. The multifaceted entity of fibromyalgia and chronic fatigue syndrome in Persian medicine and conventional medicine suggests multidisciplinary therapies in management of these disabling disorders.


2021 ◽  
Vol 6 (3) ◽  
pp. 472-478
Author(s):  
Adwitiya Ray ◽  
Neharika Saini ◽  
Ravi Parkash

Coronavirus disease 2019 (COVID-19) is a viral infection that causes various respiratory, gastrointestinal, and vascular symptoms. The acute illness phase lasts for about 2-3 weeks. However, there is increasing evidence that a percentage of COVID-19 patients continue to experience long-lasting symptoms characterized by fatigue, dyspnea, myalgia, exercise intolerance, and sleep disturbances, difficulty concentrating, anxiety, fever, headache, malaise, and vertigo. Similar symptoms are reported by patients who having myalgic encephalomyelitis/ chronic fatigue syndrome (ME/CFS). ME/CFS pathology is not known: it is thought to be multifactorial, resulting from the dysregulation of multiple systems in response to a particular trigger. There is a resemblance between post-acute COVID-19 symptoms and ME/CFS. However, at present, there is inadequate evidence to establish COVID-19 as an infectious trigger for ME/CFS. Further research is required to determine the natural history of this condition, as well as to define risk factors, prevalence, and possible interventional strategies. Keywords: chronic fatigue syndrome, COVID-19, human coronavirus, myalgic encephalomyelitis, post-infectious fatigue, review.


2021 ◽  
Author(s):  
Alison Leong ◽  
Rajeev Ramachandran ◽  
Sajini Mary Varughese ◽  
Lee Gan Goh

Abstract Lethargy is a common non-specific complaint to primary care and has a broad range of differentials. Chronic fatigue syndrome (CFS) should be considered when there is persistent fatigue affecting function and post- exertional malaise six months or longer and initial workup is not suggestive of other organic causes; it is a debilitating condition that would benefit from diagnosis and treatment. We present an adolescent with CFS, the disease timeline, its impact and outcome.


Author(s):  
Cassandra Balinas ◽  
Natalie Eaton-Fitch ◽  
Rebekah Maksoud ◽  
Donald Staines ◽  
Sonya Marshall-Gradisnik

(1) Background: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex, multifaceted illness. The pathomechanism, severity and progression of this illness is still being investigated. Stressors have been implicated in symptom exacerbation for ME/CFS, however, there is limited information for an Australian ME/CFS cohort. The aim of this study was to assess the potential effect of life stressors including changes in work, income, or family scenario on symptom severity in an Australian ME/CFS cohort over five months; (2) Methods: Australian residents with ME/CFS responded to questions relating to work, income, living arrangement, access to healthcare and support services as well as symptoms experienced; (3) Results: thirty-six ME/CFS patients (age: 41.25 ± 12.14) completed all questionnaires (response rate 83.7%). Muscle pain and weakness, orthostatic intolerance and intolerance to extreme temperatures were experienced and fluctuated over time. Sleep disturbances were likely to present as severe. Work and household income were associated with worsened cognitive, gastrointestinal, body pain and sleep symptoms. Increased access to healthcare services was associated with improved symptom presentation; (4) Conclusions: life stressors such as work and financial disruptions may significantly contribute to exacerbation of ME/CFS symptoms. Access to support services correlates with lower symptom scores.


2020 ◽  
Vol 9 (2) ◽  
pp. 76-79
Author(s):  
Justyna Szrajda ◽  

Chronic Fatigue Syndrome (CFS), also called myalgic encephalomyelitis (ME), is a condition characterized by long-term fatigue that is not significantly alleviated during rest and is not caused by previous medical conditions or continuous exercise. Symptoms are quite diverse, but not specific to this disease entity. The most common are: concentration and memory problems, sore throat, swollen lymph nodes, joint pain, sleep disturbances, headache. Moreover, autonomic nervous system functioning and post-exertional malaise examination is considered to be important in diagnosis of adolescent patients with ME/CFS. The presented analysis of research shows that adolescents with ME/CFS urge to be understood and believed regarding an illness that few understood. Continuing education and remaining the social activity in young ME/CFS patients seems to be crucial in maintaining quality of life. ME/ CFS in adolescents might lead to significant problems related to the school absenteeism, poorer quality of life at school, school and academic achievement compared to healthy adolescents. Anxiety might co-occur with ME/CFS in adolescents. Supportive therapy for comorbidities could be considered, if needed. However, there is no established effective treatment for ME/CFS, for which there is urgent need. (JNNN 2020;9(2):76–79) Key Words: ME/CFS, adolescents, Chronic Fatigue Syndrome


2015 ◽  
Vol 11 (07) ◽  
pp. 757-764 ◽  
Author(s):  
Kelli Snodgrass ◽  
Adrienne Harvey ◽  
Adam Scheinberg ◽  
Sarah Knight

Author(s):  
Jesus Castro-Marrero ◽  
Maria-Cleofé Zaragozá ◽  
Irene López-Vílchez ◽  
José Luis Galmés ◽  
Joan Carles Domingo ◽  
...  

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex, multisystem, and profoundly debilitating condition, probably of multifactorial etiology. No effective approved drugs are currently available for its treatment. Several studies have proposed symptomatic treatment with melatonin and zinc supplementation in chronic illnesses; however, little is known about the synergistic effect of this treatment on fatigue-related symptoms in ME/CFS. The primary endpoint of the study was to assess the effect of oral melatonin plus zinc supplementation on fatigue in ME/CFS. Secondary measures included participants’ sleep disturbances, anxiety/depression, and health-related quality of life. A proof-of-concept, 16-week, randomized, placebo-controlled, double-blind trial was conducted in 50 ME/CFS patients assigned to receive either oral melatonin (1 mg) plus zinc (10 mg) supplementation (n = 24) or matching placebo (n = 26) once daily. Endpoint outcomes were evaluated at baseline and then reassessed at 8 and 16 weeks of treatment and 4 weeks after treatment cessation, using self-reported outcome measures. Treatment was safe and well-tolerated. The most relevant results were the significant reduction in the perception of physical fatigue in the active group at the final follow-up versus placebo (p < 0.05), and the significant improvement in the physical component summary at all follow-up visits in the experimental group. Our findings suggest that oral melatonin plus zinc supplementation for 16 weeks is safe and potentially effective in reducing fatigue and improving the quality of life in ME/CFS. This clinical study was registered on ClinicalTrials.gov (NCT03000777).


Sign in / Sign up

Export Citation Format

Share Document